FiercePharmaOriginal article
{"a":[{"_":"Summit Therapeutics updates ivonescimab survival data ahead of FDA decision date","$":{"href":"/pharma/summit-therapeutics-updates-ivonescimab-survival-data-ahead-fda-decision-date","hreflang":"en"}}]}
Phase 3ivonescimabPositive
AI Analysis
Summary
Summit Therapeutics released updated overall survival data from the Phase 3 HARMONi trial for ivonescimab, a PD-1xVEGF bispecific antibody, ahead of an upcoming FDA decision on the drug.
Clinical Trial Data
Phase
3
Outcome Details
Updated overall survival data from HARMONi trial provided ahead of FDA decision
Importance:7/10
Sentiment:
0.60
ivonescimabPhase 3HARMONisurvival dataPD-1xVEGF bispecificFDA decision
Related Companies
Read the original article
Published by FiercePharma on July 22, 2026 10:20 AM